Acaricida

Quick links to important sections

Acaricida

Method of action: Anti-Pediculosis

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acaricida

Property Description
Active ingredient Lindane (gamma-Hexachlorocyclohexane)
Form Lotion, Shampoo, or Cream (Topical)
Pharmacological class Ectoparasiticide
General purpose Elimination of parasitic mites and lice
Origin Synthetic, Organochlorine compound

What Type of Medicine is Acaricida and What is its Composition?

Acaricida is a specialized, single-component medication identified as an Ectoparasiticide that is primarily administered via the topical route. Its action is attributed to its sole active ingredient, Lindane (gamma-Hexachlorocyclohexane), which is classified chemically as an organochlorine compound. This synthetic compound is indicated for the treatment of parasitic infestations.

Lindane is formulated in an appropriate vehicle base, such as an oil-in-water emulsion for the lotion or a detergent solution for the shampoo, allowing for direct application to the skin and hair. Lindane is an established ectoparasiticide used in human medicine for these infestations.


How is Acaricida Pharmacologically Classified?

The pharmacological class of Acaricida is Ectoparasiticide, signifying that its function is specifically to kill external parasites, such as the mites that cause scabies and various types of lice. The substance exerts a neurotoxic effect by interfering with the nervous system of the target organisms. This mechanism leads to the paralysis and death of the parasites, fulfilling the therapeutic goal of eliminating the source of infestation.

Due to its strong mechanism and chemical classification, Lindane is generally reserved for use when other, less chemically intensive treatments have failed, serving as a targeted intervention when initial therapies are insufficient.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. MedlinePlus Drug Information

What side effects are possible with Acaricida?

Possible Side Effects and Safety Information

Adverse reactions associated with Acaricida (Lindane) are categorized based on the body systems affected and their reported frequency in official regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently reported events are dermatological reactions classified as Common. These include local effects at the application site such as pruritus (itching), skin irritation, and rash.

Rare but serious adverse reactions are documented, primarily involving the Nervous System Disorders. The most clinically significant concern is the potential for seizures (convulsions), which is associated with systemic absorption, particularly when the medicine is misused or applied incorrectly. Other neurological effects listed in regulatory documents include dizziness and headache.


Population-Specific Safety Considerations and Restrictions

Official regulatory labeling includes explicit safety restrictions and notes regarding populations at increased risk of serious adverse effects due to potentially higher systemic absorption. Infants and children, older adults, and individuals with extensive or compromised skin integrity (e.g., severe psoriasis, open wounds) are documented as being at a higher risk of neurotoxicity.

Use is contraindicated in patients with a known history of uncontrolled seizure disorders or when skin barriers are compromised. Furthermore, regulatory agencies recommend that Acaricida be reserved for patients who have failed or cannot tolerate other first-line treatments, emphasizing its profile as a second-line therapeutic option. The risk of serious systemic effects, such as seizures, is strongly associated with repeated applications or prolonged exposure beyond the specified treatment duration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile by documenting the severe clinical presentations observed in humans and mandating specific emergency actions.

Overdose Presentations and Scope

Classification Official Regulatory Statements
Documented Manifestations Overdosage commonly produces Central Nervous System (CNS) depression. Specific reported outcomes include stupor, coma, delirium, hallucinations, blurred vision, muscular incoordination, rigidity, and headache.
Serious Outcomes Fatal accidental and non-accidental overdoses have been reported. Life-threatening events may include respiratory depression, shock, and seizures. Serotonin syndrome has also been reported in cases of intoxication.
High-Risk Factors Many overdoses occur in the setting of multiple drug ingestions, including alcohol, illegal drugs, or other CNS depressants. The effects of these combinations can be additive.
Emergency Actions Immediate consultation with a certified Poison Control Center is recommended in all cases of suspected overdosage. Basic life support measures, including securing a clear airway and maintaining adequate ventilation, should be initiated as dictated by the patient’s clinical presentation.

When Immediate Medical Help is Required

Urgent medical attention is required immediately upon any suspicion of overdosage. Due to the risk of life-threatening respiratory depression, shock, and seizures, individuals should be closely monitored by medical professionals. Treatment primarily focuses on supportive care and stabilization of vital signs, such as managing hypotension (low blood pressure) with intravenous fluids and vasopressor agents.

Therapeutic Uses of Acaricida

What Acaricida Treats: Main Uses and Benefits

Acaricides (or Acaricida) are compounds applied across domains where additional symptomatic support is needed to help with the management of infestations caused by external parasites, primarily mites and ticks (Acari). These agents are relevant in contexts involving heightened systemic burden, such as when conditions present with systemic or localized discomfort.

The main clinical scenarios for acaricides generally fall within veterinary medicine and pest control, targeting ectoparasites on animals. Specific formulations are commonly used for supportive management for conditions characterized by periods of heightened symptoms, such as tick and flea infestations. This approach is considered relevant for easing symptoms related to physical discomfort and systemic imbalance in host animals.

The use of an acaricide contributes to easing the overall symptom load by addressing symptom clusters that may become intense or disruptive. It assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities. This support helps manage symptom fluctuations.


Quick Fact: Relief for Symptoms Related to Physical Discomfort


Eligibility and Restrictions for Use

The official regulatory profile for Acaricida (Lindane) is highly restrictive, establishing it as a treatment for scabies or lice only after safer first-line treatments have failed.

Eligibility Scope

Populations for whom use is contraindicated:
Children under 2 years of age, including premature infants [FDA Label].
Individuals with uncontrolled seizure disorders [DailyMed].
Patients with cracked, broken, or extensively diseased skin (e.g., crusted scabies) [FDA Label].
Known hypersensitivity to Lindane or any component.

Age-related eligibility rules: The minimum age for use is 2 years. Use is restricted for individuals weighing less than 110 lbs (50 kg), regardless of age, due to an increased risk of neurotoxicity [DailyMed].

Condition-specific eligibility rules: Use is not recommended for patients with conditions that lower the seizure threshold, such as a history of head trauma, severe liver disease, or excessive alcohol use [DailyMed].

Pregnancy and lactation eligibility status: Use is not recommended during pregnancy or lactation. If used while breastfeeding, official guidelines state nursing must be interrupted for at least 24 hours following application [DailyMed].

Connection to the overall eligibility profile: Regulatory documents define the eligibility profile of Acaricida as a conditional treatment, strictly limiting use to specified adult and pediatric populations while imposing absolute contraindications based on age, seizure risk, and skin integrity to prevent potential serious neurotoxicity.

What should I know about interactions with other medicines?

Acaricida Interactions with other medicines and products

The official regulatory documentation for Acaricida (Lindane) defines interaction risks primarily by focusing on factors that increase systemic exposure and central nervous system (CNS) toxicity, rather than common metabolic drug-drug interactions.

Documented Interaction Patterns

The most significant interaction concerns are related to procedural co-application and pharmacodynamic effects, as documented by regulatory bodies:

  • Exposure-Modifying Products: The application of oils, oil-based hair and skin products, lotions, or creams is restricted because they are documented to increase the systemic absorption of Lindane. This results in greater drug exposure and a heightened risk of adverse CNS events.
  • Pharmacodynamic Caution: Caution is advised regarding co-administration with other medicinal products known to lower the seizure threshold. This represents an official warning about the potential for additive pharmacodynamic effects, specifically an enhanced risk of neurotoxicity and seizures.

Interaction-Related Constraints

The regulatory labeling imposes specific constraints to mitigate these risks:

Constraint Type Officially Documented Requirement
Timing Restriction Avoid the use of oils or oil-based products immediately prior to Acaricida application.
Population Constraint Use is formally contraindicated in patients with conditions that increase absorption, such as widespread psoriasis or excoriated (broken) skin, due to severe toxicity risk.

No specific food, alcohol, or herbal product interactions are documented in the official regulatory prescribing information.

Mechanism of Action

Non-Competitive Blockade of Inhibitory Nerve Channels

Acaricida's mechanism is defined by its selective and pronounced effect as a direct neurotoxin against external parasites. It operates primarily within two interconnected domains: targeted blockade of nerve signaling and the resulting systemic physiological collapse.

The active molecule, Lindane, initiates its action by targeting the mathbfGABA-gated chloride channel complex—the primary inhibitory receptor system in the parasite's nervous tissue. Lindane functions as a non-competitive antagonist, binding deep within the channel pore to physically prevent the influx of chloride ions (Cl^-) . This molecular blockade immediately prevents the inhibitory control that normally keeps nerve activity in check.


Induction of Unchecked Nervous System Hyperexcitation

The failure of inhibitory signals causes a rapid and unchecked neuronal hyperexcitation, representing a systemic physiological consequence of the molecular blockade. This loss of control means nerve cells continuously fire at high frequency, leading to the rapid manifestation of motor signs like tremors and convulsions. The ultimate effect of this sustained CNS overstimulation is irreversible paralysis and termination of the organism, which determines the speed and nature of the physiological collapse.

Dosage and Administration Information

How to Use Acaricida

Administration of Acaricida (Lindane) follows a single-application, time-bound topical protocol. The medicine is available in a 1% concentration as a lotion for skin application and a shampoo for application to hair and hairy areas.


Administration Guidelines

Entity Instruction
Route of administration Topical application only.
Frequency and Schedule Single application only. Re-treatment is not recommended.
Standard Dosing Lotion: A single thin-layer application of 30 mL to 60 mL is used for adults. Shampoo: A single application of 30 mL to 60 mL is applied to dry hair.
Preparation The container must be shaken well prior to use. Application must be to clean, dry skin or hair that is free of other products and has been dry for at least one hour.
Duration and Removal Lotion must remain on the skin for 8 to 12 hours and be completely washed off thereafter. Shampoo must remain on the hair for exactly 4 minutes and be rinsed off immediately.

Administration Constraints

Application consists of a single use, utilizing a specified volume for a precise contact time before complete removal. Use is restricted based on weight and age, and it is not recommended for premature infants or individuals weighing less than 110 pounds (50 kg). Additionally, the area treated with the lotion must not be covered with any occlusive or non-breathable materials, and any remaining product must be safely disposed of immediately.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acaricida

Evidence for Use in Scabies Infestation

Research examining the compound Acaricida (Lindane) for the clinical evaluation of scabies infestation primarily used short-term Randomized Controlled Trials (RCTs). These studies typically involved adults and children with a clinical diagnosis of scabies. The studies primarily monitored endpoints such as the clinical clearance measurement, which was defined in research protocols as the absence of live mites and new skin lesions, and the resolution or improvement of pruritus (itching).

In these research contexts, the findings describe patterns observed in the studies related to clearance status. Reported clearance rates for Acaricida have been observed to vary widely across different trials, with measurements ranging from approximately 45% to 86%. Comparative evidence is available, as the compound was evaluated against other common scabies treatments. Some trials described that the measured clearance rates varied in the Acaricida groups at short-term follow-up points. The research also highlights that findings were mixed regarding the consistency of clearance rates, as evidence indicates the presence of variable measurements across studies.


Evidence for Use in Head and Pubic Lice (Pediculosis) Infestation

Acaricida has also been evaluated in Randomized Controlled Trials (RCTs) and Comparative Trials for the clinical evaluation of head lice and pubic lice infestations. Research primarily focused on populations of school-aged children and adults who had confirmed lice infestations. The studies explored what outcomes were measured to determine the clearance status of the parasites, including the attainment of a lice-free measurement and the compound's effect on live lice and ova (eggs).

Findings describe patterns observed in these studies, where the compound was observed alongside other treatments for lice. Findings indicate that Acaricida’s measured effectiveness against parasite eggs (ovicidal activity) was observed to differ from some alternative treatments. An important point is that the research reports that parasite resistance has been observed in some studies, particularly for lice infestations.


Evidence Gaps and Areas of Uncertainty

What remains largely uncertain is the long-term durability of the observed response beyond the short follow-up periods used in most trials. Published data on long-term effects remain limited. Furthermore, research reports that parasite resistance has been observed, which complicates the interpretation of current research. Evidence is also limited regarding the use of Acaricida in infants and in pregnant or breastfeeding women.

Frequently Asked Questions (FAQ)

Common questions about Acaricida (FAQ)

Q: What is the main difference between Acaricida and a standard daily antihistamine?

A: Acaricida is officially classified as an Ectoparasiticide, which is a medication designed specifically to eliminate external parasites, such as mites and lice, through its action as a neurotoxin. Regulatory documents state that this drug is intended for the single topical treatment of parasitic infestations and is not classified as a drug for treating allergic symptoms or general allergy management.

Q: How quickly does Acaricida begin to show a noticeable effect on symptoms?

A: While Acaricida is a single-application treatment intended to kill the parasites, evidence indicates that successful treatment is typically confirmed during follow-up examinations (usually 2 to 4 weeks after application). Itching (pruritus) is a common reaction to the infestation that can persist for one to several weeks even after all parasites have been eliminated. Therefore, persistent itching is typically not considered an indicator of treatment failure.

Q: How long do the mild, local side effects usually persist after starting treatment?

A: According to official product information, common local side effects like skin irritation, rash, or residual itching (pruritus) at the application site can often persist for one to several weeks following the single application. These reactions are dermatological in nature. They may sometimes be addressed with other products (such as topical corticosteroids or oral antihistamines), but they are not generally considered an indication for re-treatment with Acaricida.

Q: What are the signs of a severe allergic reaction that would require stopping Acaricida?

A: Although a very serious allergic reaction is listed as a potential, unlikely side effect, official documentation outlines certain signs of severe hypersensitivity. These may include a generalized rash, swelling (especially of the face, tongue, or throat), severe dizziness, or trouble breathing. Serious nervous system disorders, such as seizures, are also listed as rare but clinically significant adverse reactions.

Q: Is it safe to continue Acaricida if I develop a cold or throat irritation?

A: Acaricida is strictly a topical product. Official guidelines strictly advise users to avoid contact with sensitive areas such as the eyes, nose, or mouth during application. Furthermore, the official label advises caution or avoidance if there is extensive skin irritation, cuts, or sores in the area to be treated. This precaution is due to the potential for increased systemic absorption in areas where the skin barrier is compromised.

Q: Does Acaricida interact with common over-the-counter pain relievers like ibuprofen?

A: The regulatory label provides a precaution regarding the concomitant use of Acaricida with any medicinal products known to lower the seizure threshold, due to a potential increased risk of neurotoxicity. However, official documents do not specifically name common over-the-counter pain relievers like ibuprofen or acetaminophen in this caution.

Q: Is moderate alcohol consumption safe during Acaricida treatment?

A: Regulatory documents indicate that the product is not recommended for patients with conditions that increase the risk of seizures, and this specifically includes individuals with a history of excessive use of alcohol or those undergoing abrupt withdrawal. There is no explicit statement in the official warnings or precautions regarding the safety profile of moderate or occasional alcohol consumption during the treatment period.

Q: Are there any known side effects of Acaricida on the stomach or digestive system?

A: Since Acaricida is intended only for topical application, official side effect listings focus primarily on dermatological and nervous system issues. Acute exposure via prohibited oral ingestion has, however, been associated in regulatory documents with gastrointestinal effects. These effects include symptoms such as nausea, vomiting, abdominal pain, and diarrhea.

Q: Does Acaricida affect my ability to drive or operate machinery?

A: Official safety information indicates that adverse effects of Acaricida can include dizziness and drowsiness (somnolence). Caution may be warranted if performing activities requiring mental alertness, as central nervous system stimulation or impairment can occur following product exposure.

Q: Do I need to continue to take my existing asthma medications while on Acaricida?

A: Acaricida (Lindane) is clearly indicated by regulatory agencies as an Ectoparasiticide to eliminate parasitic infestations like scabies and lice. It is not indicated for the treatment, management, or prevention of asthma or its related symptoms. Therefore, official guidelines do not address the need to adjust existing maintenance asthma medications, as Acaricida is not indicated for the management of asthma.

Q: Can Acaricida make my existing allergy symptoms temporarily worse when I start?

A: The most common side effects listed in official documents are local reactions at the application site, such as pruritus (itching), skin irritation, and rash. Since itching is a core symptom of the underlying infestation, official sources indicate that this itching may persist or even appear to worsen temporarily after successful treatment.

Q: Does Acaricida contain any common food allergens, such as fish protein?

A: The official product components listed are the active ingredient, Lindane, and various inactive vehicle base ingredients (such as water, citric acid, and emulsifiers). Regulatory documentation provides a detailed list of these components, and no mention of common food allergens, such as fish protein, is provided.

How should Acaricida be stored and disposed of?

How to Store and Dispose of Acaricida?


Proper storage and disposal are essential for maintaining the efficacy and safety of Acaricida. This medication should be stored at room temperature, typically between 68^circmathrmF and 77^circmathrmF (20^circmathrmC and 25^circmathrmC). Keep it in its original container, tightly closed, and away from moisture, heat, and direct light. Do not store Acaricida in the bathroom.

Disposal Guidelines

Action Instruction
Do NOT Flush down the toilet or pour down a drain unless specifically instructed to do so.
Recommended Dispose of expired or unused medication through a community drug take-back program or a mail-back program provided by the manufacturer.
Alternative If no take-back program is available, mix the medication with an unappealing substance (like dirt or used coffee grounds), place it in a sealed bag, and discard it in the household trash.

Keep all medications out of the reach of children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acaricida found in:

A-Z Index: